-
12/18/2017
PAION grants exclusive license to Mundipharma for development and commercialization of remimazolam in Japan
-
12/06/2017
Jürgen Beck, MD appointed as Chief Development Officer at PAION AG
-
11/23/2017
PAION announces clinical development progress with remimazolam by its partner Hana Pharm in South Korea
-
11/14/2017
FDA considers current human abuse liability program with Remimazolam in the U.S. as sufficient; no second intranasal study required
-
10/19/2017
PAION to host remimazolam symposium at Japan Society for Clinical Anesthesia Annual Meeting in Japan
-
10/18/2017
Remimazolam Phase III broncoscopy data to be presented at the Chest Annual Meeting 2017
-
10/13/2017
Japan patent office grants dosing patent for remimazolam in Japan
-
09/28/2017
European Patent Office grants formulation patent for remimazolam in the EU
-
08/09/2017
PAION AG reports financial results for the first half-year of 2017
-
08/07/2017
PAION announces clinical development progress with remimazolam by its partner R-Pharm in Russia
-
07/17/2017
PAION AG raises EUR 8.0 million in private placement
-
06/28/2017
PAION AG: PAION reports positive headline data in U.S. Phase III trial with remimazolam for procedural sedation during bronchoscopy
-
05/17/2017
PAION AG: Annual General Meeting approves all agenda items and elects Dr. Dr. Irina Antonijevic and Dr. Chris Tanner to the Supervisory Board
-
03/28/2017
PAION successfully completes patient recruitment in U.S. Phase III study with remimazolam for procedural sedation during bronchoscopy
-
03/27/2017
PAION reports positive headline data in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy
-
03/16/2017
PAION AG reports on fiscal year and financial results 2016
-
03/09/2017
PAION AG: Change in Management Board
-
02/28/2017
PAION AG announces successful completion of capital increase with subscription rights
-
02/07/2017
PAION AG: Capital increase; preliminary, unaudited key Group figures for 2016